Barclays’s ProShares Ultra CRCL CRCA Stock Holding History

Barclays’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000	Closed	-$40.4K	–	5563
2025 Q4	$40.4K	Hold	1,000	–	–	﹤0.01%	4769
2025 Q3	$146K	Buy	+1,000	New	+$161K	﹤0.01%	4497

Other funds holding CRCA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Barclays's CRCA Position: Q1 2026 in Review

Barclays sold out of ProShares Ultra CRCL (CRCA) in Q1 2026, closing a stake of 1,000 shares — an estimated $40.4K sold.

Barclays first reported a position in CRCA in Q3 2025 and held it in 2 quarters. The position peaked at $146K in Q3 2025. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

Barclays reported no remaining ProShares Ultra CRCL position as of Q1 2026 after selling out during the quarter.
Barclays sold 1,000 ProShares Ultra CRCL shares in Q1 2026, an estimated $40.4K.
Barclays first reported a position in ProShares Ultra CRCL in Q3 2025 and held it in 2 quarters.
Barclays's ProShares Ultra CRCL position peaked at $146K in Q3 2025.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.